Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

Takahiro Nakayama(University of Shizuoka), Norikazu Masuda(Kyoto University), Masato Takahashi(National Hospital Organization Hokkaido Medical Center), Nobuyoshi Kittaka(Osaka International Cancer Institute), Takehiko Takata(Daiichi-Sankyo (Japan)), Tetsuhiro Yoshinami, Hiroyuki Yasojima(Osaka National Hospital), Naoko Yamamoto(Disco (japan)), Seung Jin Kim(The University of Osaka), Tomomi Yamada(Osaka University Hospital), Shoichiro Ohtani(Hiroshima Prefectural Rehabilitation Center), Hiroyuki Kurakami(Osaka University Hospital)
BMC Cancer
July 9, 2021
10.1186/s12885-021-08504-1
Cited by 7

Related Papers

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
|Circulation|2017|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Prevention of Infective Endocarditis
|Circulation|2007|2.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k